Ind-Swift Laboratories Ltd
INDSWFTLAB
Company Profile
Business description
Ind-Swift Laboratories Ltd is engaged in the business of manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. It operates in a single segment namely, Bulk Drugs and Pharmaceuticals. Geographically, the company caters to both Indian and international markets, of which, maximum revenue is derived from outside India.
Contact
SCO 850, NAC
Shivalik Enclave
Manimajra
ChandigarhPB160101
INDT: +91 1725061850
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
47
Stocks News & Analysis
stocks
Anglo American strikes deal to create a new copper giant
We are surprised that Teck agreed to the merger on these terms, and wouldn’t be surprised if there is a twist in the tale.
stocks
The ‘other’ AI chip behemoth that might just be getting started
The magnitude of growth at Broadcom continues to astound us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,071.40 | 9.10 | -0.10% |
| CAC 40 | 7,824.23 | 62.91 | 0.81% |
| DAX 40 | 23,678.85 | 45.90 | 0.19% |
| Dow JONES (US) | 45,490.92 | 220.42 | -0.48% |
| FTSE 100 | 9,267.89 | 42.50 | 0.46% |
| HKSE | 26,086.32 | 113.94 | -0.43% |
| NASDAQ | 21,886.06 | 6.57 | 0.03% |
| Nikkei 225 | 44,372.50 | 534.83 | 1.22% |
| NZX 50 Index | 13,229.15 | 47.09 | -0.35% |
| S&P 500 | 6,532.04 | 19.43 | 0.30% |
| S&P/ASX 200 | 8,805.00 | 8.80 | -0.10% |
| SSE Composite Index | 3,875.31 | 63.09 | 1.65% |